StreetAlpha.app
Home › Stocks › TRVI

Trevi Therapeutics, Inc. (TRVI)

Healthcare
$13.51
▲ +1.66%
LAST CLOSE · NOV 17

Trevi Therapeutics is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough in lung disease patients. It last closed at $13.51 on Nov 17, up 1.66% on the day. TRVI last reported earnings on Mon, Nov 9, 2026. Over the past 90 days StreetAlpha recorded 1 whale options trade in TRVI, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is TRVI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$60.8M
EPS (diluted)
−$0.40
Free cash flow
−$61.7M
Valuation
Market cap
$1.9B
142.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.8M
At Sep 30
Shareholder equity
$302.8M
Shares outstanding
142.6M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$33.9M−$33.9MFY2021FY2022: −$29.2M−$29.2MFY2022FY2023: −$29.1M−$29.1MFY2023FY2024: −$47.9M−$47.9MFY2024FY2025: −$42.8M−$42.8MFY2025

From TRVI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · After the close (AMC)
Reported EPS
-$0.13
vs -$0.13 est. · inline
Year-ago EPS
-$0.08
Same quarter last year
Options-implied move
±11.3%
Priced in before that report
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated TRVI in the past 90 days.
Average 12-month target
No price targets on TRVI in the past 90 days.
Latest rating changes
Jones TradingMaintained
Aug 14Buy$28
OppenheimerMaintained
Aug 7Buy$25
Cantor FitzgeraldMaintained
Aug 7Buy$30
BMO CapitalInitiated
Jul 21Buy$36
B. Riley SecuritiesMaintained
Jul 20Buy$31
DateFirmActionRatingPrice target
Aug 14Jones TradingMaintainedBuy$28
Aug 7OppenheimerMaintainedBuy$25
Aug 7Cantor FitzgeraldMaintainedBuy$30
Jul 21BMO CapitalInitiatedBuy$36
Jul 20B. Riley SecuritiesMaintainedBuy$31
Loading…

Technical Analysis

TRVI · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 1% below its 20 day and 3% below its 50 day average. It is 8% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $13.34, and the nearest resistance the 20 day average at $13.64.

Short trendNeutral
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityHigh, 6.2%/day
Key levels
$20.2252 week high+49.7%
$15.91100 day average+17.8%
$14.75Swing high (May 27)+9.2%
$14.55200 day average+7.7%
$13.8950 day average+2.8%
$13.78Pivot R1+2.0%
$13.6420 day average+1.0%
$13.51Last close
$13.34Pivot−1.3%
$13.25Swing low (Jun 3)−1.9%
$13.06Pivot S1−3.3%
$9.8252 week low−27.3%
Indicators
RSI (14)47.64Middle of its rangeNeutral
MACD0.03Above its signal lineBullish
Stochastic27.7Middle of its rangeNeutral
ADX (14)21.8Weak trend
Williams %R-73.6Oversold below −80, overbought above −20Neutral
CCI (20)-34.5Oversold below −100, overbought above 100Neutral
Rate of change−2.5%Change over 10 sessionsBearish
ATR (14)$0.84Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TRVI

What happened before

See how TRVI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TRVI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TRVI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 29 – Sep 29
Loading…

See today’s whale options flow across the market →

TRVI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲119 buying vs 88 selling
  • ●Held by funds +0.4 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding223218+2.3%
In funds' top 101012−16.7%
Held by funds106.1%105.7%+0.4 pts
New / increased36 / 8339 / 88−6.3%
Reduced / sold out57 / 3158 / 20+12.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TRVI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRVI is in one of them and how their past TRVI trades turned out.

TRVI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TRVI in an article yet. Here's the latest on the wider market.

About Trevi Therapeutics

Trevi Therapeutics is a biopharmaceutical company based in New Haven, Connecticut, in the United States. It is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough. The drug is in clinical trials for patients with idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough. Nalbuphine has been used as an injectable pain medicine for decades, and the company holds worldwide commercial rights to Haduvio.

Headquarters
New Haven, CT